Procter & Gamble
PG
159.32
+1.63
+1.03%
Procter & Gamble
US · PG
#46 by market cap
Listed 1970
159.32
+1.63
+1.03%
Live - 5344 symbols - heartbeat 222s ago
· 2026-10-20 21:13
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.66, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.26% YoY
Margins
- Gross margin
- 50.18%
- Operating margin
- 22.69%
- Net margin
- 18.10%
Key ratios & quality
- Enterprise valuei
- 394.49B
- PEG ratioi
- 7.83
- Altman Z-Scorei
- 5.66
PEG uses trailing P/E against the 3-year net income growth rate (3.07%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67.68B | 70.95B | 76.12B | 80.19B | 82.01B | 84.04B | 84.28B | 87.03B |
| Gross profit | 32.92B | 35.70B | 39.01B | 38.03B | 39.25B | 43.19B | 43.12B | 43.67B |
| Selling & admin expenses | 19.08B | 19.99B | 21.02B | 20.22B | 21.11B | 23.31B | 22.67B | 23.92B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 13.83B | 15.71B | 17.99B | 17.81B | 18.13B | 19.89B | 20.45B | 19.75B |
| Pretax profit | 6.07B | 15.83B | 17.62B | 18.00B | 18.35B | 18.76B | 20.17B | 20.38B |
| Tax | 2.10B | 2.73B | 3.26B | 3.20B | 3.62B | 3.79B | 4.10B | 4.23B |
| Net profit | 3.97B | 13.10B | 14.35B | 14.79B | 14.74B | 14.97B | 16.07B | 16.14B |
| Basic EPS | 1 | 5 | 6 | 6 | 6 | 6 | 7 | 7 |
| Diluted EPS | 1.43 | 4.96 | 5.50 | 5.81 | 5.90 | 6.02 | 6.51 | 6.62 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 19.78B | 20.89B | 22.39B | 22.21B | 21.24B | 21.20B |
| Gross profit | 10.08B | 10.26B | 11.50B | 11.37B | 10.51B | 10.28B |
| Selling & admin expenses | 5.52B | 5.90B | 5.64B | 6.01B | 5.94B | 6.33B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 4.56B | 4.35B | 5.86B | 5.37B | 4.58B | 3.95B |
| Pretax profit | 4.66B | 4.52B | 6.03B | 5.42B | 4.99B | 3.93B |
| Tax | 868.00M | 895.00M | 1.25B | 1.09B | 1.04B | 852.00M |
| Net profit | 3.79B | 3.63B | 4.78B | 4.33B | 3.95B | 3.08B |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 1 |
| Diluted EPS | 1.54 | 1.48 | 1.95 | 1.78 | 1.63 | 1.26 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 22.47B | 27.99B | 23.09B | 21.65B | 22.65B | 24.71B | 25.39B | 26.21B |
| Cash & ST investments | 10.29B | 16.18B | 10.29B | 7.21B | 8.25B | 9.48B | 9.56B | 9.94B |
| Inventory | 5.02B | 5.50B | 5.98B | 6.92B | 7.07B | 7.02B | 7.55B | 8.17B |
| Total assets | 115.10B | 120.70B | 119.31B | 117.21B | 120.83B | 122.37B | 125.23B | 126.52B |
| Total current liabilities | 30.01B | 32.98B | 33.13B | 33.08B | 35.76B | 33.63B | 36.06B | 38.69B |
| Short-term debt | 9.70B | 11.42B | 9.11B | 8.85B | 10.45B | 7.43B | 9.77B | 11.54B |
| Long-term debt | 20.40B | 23.54B | 23.10B | 22.85B | 24.38B | 25.27B | 25.00B | 22.84B |
| Total liabilities | 67,516,000,000.00 | 73,822,000,000.00 | 72,653,000,000.00 | 70,354,000,000.00 | 73,764,000,000.00 | 71,812,000,000.00 | 72,947,000,000.00 | 72,210,000,000.00 |
| Total equity | 47.58B | 46.88B | 46.65B | 46.85B | 47.07B | 50.56B | 52.28B | 54.31B |
| Retained earnings | 94.92B | 100.24B | 106.37B | 112.43B | 118.17B | 123.81B | 129.97B | 135.85B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 24.44B | 25.39B | 27.12B | 26.59B | 27.99B | 26.21B |
| Cash & ST investments | 9.12B | 9.56B | 11.17B | 10.83B | 12.31B | 9.94B |
| Inventory | 7.40B | 7.55B | 7.85B | 7.82B | 7.85B | 8.17B |
| Total assets | 122.98B | 125.23B | 127.60B | 127.29B | 128.38B | 126.52B |
| Total current liabilities | 34.25B | 36.06B | 38.00B | 36.70B | 38.24B | 38.69B |
| Short-term debt | 9.89B | 9.77B | 11.63B | 11.06B | 13.17B | 11.54B |
| Long-term debt | 24.25B | 25.00B | 24.32B | 25.58B | 23.85B | 22.84B |
| Total liabilities | 70,439,000,000.00 | 72,947,000,000.00 | 74,048,000,000.00 | 73,969,000,000.00 | 73,647,000,000.00 | 72,210,000,000.00 |
| Total equity | 52.55B | 52.28B | 53.55B | 53.32B | 54.73B | 54.31B |
| Retained earnings | 128.92B | 129.97B | 132.21B | 133.98B | 135.42B | 135.85B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 15.24B | 17.40B | 18.37B | 16.72B | 16.85B | 19.85B | 17.82B | 19.56B |
| Depreciation & amortization | 2.82B | 3.01B | 2.74B | 2.81B | 2.71B | 2.90B | 2.85B | 3.16B |
| Free cash flow | 11.90B | 14.33B | 15.58B | 13.57B | 13.79B | 16.52B | 14.04B | 15.15B |
| Dividends paid | -7.50B | -7.79B | -8.26B | -8.77B | -9.00B | -9.31B | -9.87B | -10.23B |
| Stock buybacks / issuance | -5.00B | -7.41B | -11.01B | -10.00B | -7.35B | -5.01B | -6.50B | -5.03B |
| Ending cash balance | 4.24B | 16.18B | 10.29B | 7.21B | 8.25B | 9.48B | 9.56B | 9.94B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.71B | 4.99B | 5.41B | 4.97B | 4.05B | 5.13B |
| Depreciation & amortization | 690.00M | 723.00M | 761.00M | 802.00M | 785.00M | 812.00M |
| Free cash flow | 2.85B | 3.99B | 4.21B | 3.81B | 3.03B | 4.11B |
| Dividends paid | -2.43B | -2.55B | -2.55B | -2.54B | -2.53B | -2.61B |
| Stock buybacks / issuance | -1.35B | -700.00M | -1.25B | -2.28B | -625.00M | -875.00M |
| Ending cash balance | 9.12B | 9.56B | 11.17B | 10.83B | 12.31B | 9.94B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.45 | 27.78 | 30.80 | 31.69 | 31.34 | 30.58 | 31.14 | 30.13 |
| ROA %i | 3.11 | 10.83 | 11.70 | 12.23 | 12.07 | 12.00 | 12.67 | 12.52 |
| ROIC %i | 4.81 | 16.55 | 18.08 | 18.90 | 18.48 | 18.21 | 18.91 | 18.40 |
| 5-year avg ROE %i | 16.13 | 19.59 | 22.26 | 23.14 | 25.81 | 30.44 | 31.11 | 30.98 |
| EBIT margin %i | 9.72 | 22.97 | 23.80 | 22.99 | 23.30 | 23.42 | 25.00 | 24.42 |
| FCF / sales %i | 17.57 | 20.20 | 20.47 | 16.92 | 16.81 | 19.66 | 16.66 | 17.40 |
| Current ratioi | 0.75 | 0.85 | 0.70 | 0.65 | 0.63 | 0.73 | 0.70 | 0.68 |
| Quick ratioi | 0.51 | 0.62 | 0.45 | 0.37 | 0.38 | 0.46 | 0.44 | 0.41 |
| Debt / assetsi | 26.15 | 29.50 | 27.52 | 27.55 | 29.32 | 27.27 | 28.32 | 27.68 |
| LT debt / equityi | 44.08 | 53.02 | 52.14 | 51.25 | 54.34 | 52.41 | 50.15 | 44.04 |
| Interest coveragei | 12.92 | 35.05 | 36.09 | 41.99 | 25.28 | 21.28 | 23.23 | 24.23 |
| Revenue CAGR (3Y) %i | 1.20 | 2.93 | 4.43 | 5.81 | 4.95 | 3.35 | 1.67 | 2.00 |
| Net income CAGR (3Y) %i | -28.15 | -5.27 | 13.63 | 55.81 | 4.00 | 1.32 | 2.71 | 3.07 |
| FCF CAGR (3Y) %i | -0.63 | 15.22 | 11.81 | 4.48 | -1.28 | 1.97 | 1.16 | 3.19 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 30.19 | 31.14 | 31.81 | 31.49 | 31.02 | 30.13 |
| ROA %i | 12.54 | 12.67 | 12.97 | 12.93 | 12.99 | 12.52 |
| ROIC %i | 18.65 | 18.91 | 19.14 | 18.95 | 18.89 | 18.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 24.34 | 25.00 | 25.82 | 25.20 | 25.16 | 24.42 |
| FCF / sales %i | 17.90 | 16.66 | 17.59 | 17.42 | 17.33 | 17.40 |
| Current ratioi | 0.71 | 0.70 | 0.71 | 0.72 | 0.73 | 0.68 |
| Quick ratioi | 0.45 | 0.44 | 0.46 | 0.47 | 0.49 | 0.41 |
| Debt / assetsi | 27.76 | 28.32 | 28.17 | 28.78 | 28.84 | 27.68 |
| LT debt / equityi | 47.10 | 50.15 | 46.31 | 48.93 | 44.38 | 44.04 |
| Interest coveragei | 22.33 | 23.23 | 25.32 | 25.39 | 25.58 | 24.23 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Fabric & Home Care is the largest reported line at 34.83% of revenue, across 6 reported segments.
- No single line clears half of revenue; Baby, Feminine & Family Care is next at 23.44%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Fabric & Home Care34.83%
Baby, Feminine & Family Care23.44%
Beauty18.41%
Health Care14.31%
GROOMING7.95%
Corporate1.06%
Region
International52.07%
United States47.93%
Quote time 2026-10-20 21:13:58 · For reference only, not investment advice and not tailored to your situation.
pricing power held up better than most consumer names through the recent stretch. not a stock that excites anyone at a dinner party but it does exactly what it’s supposed to do in a portfolio.